Y-Intercept (HK)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Y-Intercept (HK)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$628K	Sell	10,976 -67,362	-86%	-$3.69M	0.01%	1239
2026 Q1	$4.43M	Sell	78,338 -29,627	-27%	-$1.73M	0.08%	367
2025 Q4	$6.42M	Buy	107,965 +17,456	+19%	+$950K	0.14%	150
2025 Q3	$4.9M	Sell	90,509 -51,159	-36%	-$2.93M	0.12%	213
2025 Q2	$7.79M	Buy	141,668 +137,443	+3,253%	+$8.09M	0.19%	115
2025 Q1	$299K	Sell	4,225 -486	-10%	-$32.7K	0.02%	909
2024 Q4	$310K	Sell	4,711 -23,519	-83%	-$1.58M	0.02%	926
2024 Q3	$1.98M	Buy	+28,230	New	+$2.36M	0.12%	213
2023 Q3	–	Sell	-9,384	Closed	-$813K	–	1088
2023 Q2	$813K	Buy	+9,384	New	+$883K	0.09%	373
2023 Q1	–	Sell	-14,769	Closed	-$1.53M	–	1189
2022 Q4	$1.53M	Buy	14,769 +10,213	+224%	+$959K	0.23%	103
2022 Q3	$386K	Buy	+4,556	New	+$406K	0.04%	628
2022 Q2	–	Sell	-6,487	Closed	-$500K	–	874
2022 Q1	$500K	Buy	6,487 +3,664	+130%	+$307K	0.11%	264
2021 Q4	$249K	Buy	+2,823	New	+$233K	0.06%	452
2021 Q3	–	Sell	-21,479	Closed	-$1.79M	–	656
2021 Q2	$1.79M	Buy	+21,479	New	+$1.7M	0.46%	25
2021 Q1	–	Sell	-5,103	Closed	-$444K	–	630
2020 Q4	$444K	Buy	+5,103	New	+$405K	0.19%	187

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Y-Intercept (HK)'s BMRN Position: Q2 2026 in Review

Y-Intercept (HK) reduced its BioMarin Pharmaceuticals (BMRN) stake by 86% in Q2 2026, selling an estimated $3.69M and leaving 10,976 shares worth $628K. The position accounts for 0.01% of the portfolio, ranked #1239.

Y-Intercept (HK) first reported a position in BMRN in Q4 2020 and has held it in 15 quarters since. The position peaked at $7.79M in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Y-Intercept (HK) held 10,976 shares of BioMarin Pharmaceuticals worth $628K as of Q2 2026.
Y-Intercept (HK) sold 67,362 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.69M.
BioMarin Pharmaceuticals made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1239 holding.
Y-Intercept (HK) first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
Y-Intercept (HK)'s BioMarin Pharmaceuticals position peaked at $7.79M in Q2 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.